Sildenafil in ophthalmology: An update

Surv Ophthalmol. 2022 Mar-Apr;67(2):463-487. doi: 10.1016/j.survophthal.2021.06.004. Epub 2021 Jun 25.

Abstract

Sildenafil citrate, a selective oral phosphodiesterase 5 inhibitor, is a widely used drug for erectile dysfunction that acts by elevating cGMP levels and causing smooth muscle relaxation. It also has 10% activity against PDE6, a key enzyme in phototransduction cascade in the retina. Recent ocular imaging developments have further revealed the influence of sildenafil on ocular hemodynamics, particularly choroidal perfusion. Choroidal thickness is increased, and choroidal perfusion is also enhanced by autoregulatory mechanisms that are further dependent on age and microvascular abnormalities. Studies demonstrating high intraocular pressure via a "parallel pathway" from increased choroidal volume and blood flow to the ciliary body have challenged previous concepts. Another new observation is the effect of sildenafil on bipolar cells and cyclic-nucleotide gated channels. We discuss potential deleterious effects (central serous chorioretinopathy, glaucoma, ischemic optic neuropathy, and risks to recessive carriers of retinitis pigmentosa), potential beneficial effects (ameliorate choroidal ischemia, prevent thickening of Bruch membrane, and promote recovery of the ellipsoid zone) in macular degeneration, as well as potential drug interactions of sildenafil.

Keywords: Age related macular degeneration; Central serous chorioretinopathy; Choroidal perfusion; Choroidal thickness; Erectile dysfunction; Phosphodiesterase inhibitor; Retinitis pigmentosa; Sildenafil; Viagra.

Publication types

  • Review

MeSH terms

  • Choroid / blood supply
  • Humans
  • Male
  • Ophthalmology*
  • Piperazines / pharmacology
  • Purines / pharmacology
  • Purines / therapeutic use
  • Sildenafil Citrate / pharmacology
  • Sildenafil Citrate / therapeutic use
  • Sulfones / pharmacology

Substances

  • Piperazines
  • Purines
  • Sulfones
  • Sildenafil Citrate